Increasing the performance of pooled CRISPR–Cas9 drop-out screening
Citations Over TimeTop 14% of 2016 papers
Abstract
Components of the type II CRISPR-Cas complex in bacteria have been used successfully in eukaryotic cells to facilitate rapid and accurate cell line engineering, animal model generation and functional genomic screens. Such developments are providing new opportunities for drug target identification and validation, particularly with the application of pooled genetic screening. As CRISPR-Cas is a relatively new genetic screening tool, it is important to assess its functionality in a number of different cell lines and to analyse potential improvements that might increase the sensitivity of a given screen. To examine critical aspects of screening quality, we constructed ultra-complex libraries containing sgRNA sequences targeting a collection of essential genes. We examined the performance of screening in both haploid and hypotriploid cell lines, using two alternative guide design algorithms and two tracrRNA variants in a time-resolved analysis. Our data indicate that a simple adaptation of the tracrRNA substantially improves the robustness of guide loss during a screen. This modification minimises the requirement for high numbers of sgRNAs targeting each gene, increasing hit scoring and creating a powerful new platform for successful screening.
Related Papers
- → CRISPR-Cas9 system: A new-fangled dawn in gene editing(2019)310 cited
- → Temperature effect on CRISPR-Cas9 mediated genome editing(2017)108 cited
- → Unintended CRISPR-Cas9 editing outcomes: a review of the detection and prevalence of structural variants generated by gene-editing in human cells(2023)98 cited
- → Therapeutic applications of CRISPR RNA-guided genome editing(2016)25 cited
- → CRISPR/Cas9 system: A promising technology for the treatment of inherited and neoplastic hematological diseases(2018)17 cited